143 related articles for article (PubMed ID: 32798651)
1. Discovery of a phenylpyrazole amide ROCK inhibitor as a tool molecule for in vivo studies.
Hu Z; Wang C; Glunz PW; Li J; Cheadle NL; Chen AY; Chen XQ; Myers JE; Guarino VR; Rose A; Sack JS; Sitkoff D; Taylor DS; Xu S; Yan C; Zhang H; Zhang L; Hennan J; Adam LP; Wexler RR; Quan ML
Bioorg Med Chem Lett; 2020 Nov; 30(21):127495. PubMed ID: 32798651
[TBL] [Abstract][Full Text] [Related]
2. Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.
Feng Y; Yin Y; Weiser A; Griffin E; Cameron MD; Lin L; Ruiz C; Schürer SC; Inoue T; Rao PV; Schröter T; Lograsso P
J Med Chem; 2008 Nov; 51(21):6642-5. PubMed ID: 18834107
[TBL] [Abstract][Full Text] [Related]
3. Identification of 5H-chromeno[3,4-c]pyridine and 6H-isochromeno[3,4-c]pyridine derivatives as potent and selective dual ROCK inhibitors.
Hu Z; Wang C; Sitkoff D; Cheadle NL; Xu S; Muckelbauer JK; Adam LP; Wexler RR; Quan ML
Bioorg Med Chem Lett; 2020 Nov; 30(21):127474. PubMed ID: 32805407
[TBL] [Abstract][Full Text] [Related]
4. Discovery of (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide as potent and isoform selective ROCK2 inhibitors.
Pan J; Yin Y; Zhao L; Feng Y
Bioorg Med Chem; 2019 Apr; 27(7):1382-1390. PubMed ID: 30819619
[TBL] [Abstract][Full Text] [Related]
5. Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.
Hobson AD; Judge RA; Aguirre AL; Brown BS; Cui Y; Ding P; Dominguez E; DiGiammarino E; Egan DA; Freiberg GM; Gopalakrishnan SM; Harris CM; Honore MP; Kage KL; Kapecki NJ; Ling C; Ma J; Mack H; Mamo M; Maurus S; McRae B; Moore NS; Mueller BK; Mueller R; Namovic MT; Patel K; Pratt SD; Putman CB; Queeney KL; Sarris KK; Schaffter LM; Stoll V; Vasudevan A; Wang L; Wang L; Wirthl W; Yach K
J Med Chem; 2018 Dec; 61(24):11074-11100. PubMed ID: 30384606
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.
Green J; Cao J; Bandarage UK; Gao H; Court J; Marhefka C; Jacobs M; Taslimi P; Newsome D; Nakayama T; Shah S; Rodems S
J Med Chem; 2015 Jun; 58(12):5028-37. PubMed ID: 26039570
[TBL] [Abstract][Full Text] [Related]
7. Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension.
Shaw D; Hollingworth G; Soldermann N; Sprague E; Schuler W; Vangrevelinghe E; Duggan N; Thomas M; Kosaka T; Waters N; van Eis MJ
Bioorg Med Chem Lett; 2014 Oct; 24(20):4812-7. PubMed ID: 25248678
[TBL] [Abstract][Full Text] [Related]
8. A review on ROCK-II inhibitors: From molecular modelling to synthesis.
Shah S; Savjani J
Bioorg Med Chem Lett; 2016 May; 26(10):2383-2391. PubMed ID: 27080184
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK).
Smith AL; Andrews KL; Beckmann H; Bellon SF; Beltran PJ; Booker S; Chen H; Chung YA; D'Angelo ND; Dao J; Dellamaggiore KR; Jaeckel P; Kendall R; Labitzke K; Long AM; Materna-Reichelt S; Mitchell P; Norman MH; Powers D; Rose M; Shaffer PL; Wu MM; Lipford JR
J Med Chem; 2015 Feb; 58(3):1426-41. PubMed ID: 25587754
[TBL] [Abstract][Full Text] [Related]
10. ROCK inhibitors 4: Structure-activity relationship studies of 7-azaindole-based rho kinase (ROCK) inhibitors.
Bandarage UK; Court J; Gao H; Nanthakumar S; Come JH; Giroux S; Green J
Bioorg Med Chem Lett; 2021 Feb; 33():127721. PubMed ID: 33259926
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).
Degorce SL; Boyd S; Curwen JO; Ducray R; Halsall CT; Jones CD; Lach F; Lenz EM; Pass M; Pass S; Trigwell C
J Med Chem; 2016 May; 59(10):4859-66. PubMed ID: 27078757
[TBL] [Abstract][Full Text] [Related]
12. Discovery of hydroxyaniline amides as selective Extracellular Regulated Kinase (Erk) inhibitors.
Zhu HY; Desai J; Deng Y; Cooper A; Wang J; Shipps J; Samatar A; Carr D; Windsor W
Bioorg Med Chem Lett; 2015 Apr; 25(7):1627-9. PubMed ID: 25716905
[TBL] [Abstract][Full Text] [Related]
13. A novel small-molecule MRCK inhibitor blocks cancer cell invasion.
Unbekandt M; Croft DR; Crighton D; Mezna M; McArthur D; McConnell P; Schüttelkopf AW; Belshaw S; Pannifer A; Sime M; Bower J; Drysdale M; Olson MF
Cell Commun Signal; 2014 Oct; 12():54. PubMed ID: 25288205
[TBL] [Abstract][Full Text] [Related]
14. Design of Aminobenzothiazole Inhibitors of Rho Kinases 1 and 2 by Using Protein Kinase A as a Structure Surrogate.
Judge RA; Vasudevan A; Scott VE; Simler GH; Pratt SD; Namovic MT; Putman CB; Aguirre A; Stoll VS; Mamo M; Swann SI; Cassar SC; Faltynek CR; Kage KL; Boyce-Rustay JM; Hobson AD
Chembiochem; 2018 Mar; 19(6):613-621. PubMed ID: 29314498
[TBL] [Abstract][Full Text] [Related]
15. Optimization and in vivo evaluation of pyrazolopyridines as a potent and selective PI3Kδ inhibitor.
Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Moritomo A; Kubo S; Nakamura K; Yamagami K; Hamakawa N; Yokoo K; Fukahori H
Bioorg Med Chem; 2018 Aug; 26(14):3917-3924. PubMed ID: 29907471
[TBL] [Abstract][Full Text] [Related]
16. Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.
Ellis JM; Altman MD; Bass A; Butcher JW; Byford AJ; Donofrio A; Galloway S; Haidle AM; Jewell J; Kelly N; Leccese EK; Lee S; Maddess M; Miller JR; Moy LY; Osimboni E; Otte RD; Reddy MV; Spencer K; Sun B; Vincent SH; Ward GJ; Woo GH; Yang C; Houshyar H; Northrup AB
J Med Chem; 2015 Feb; 58(4):1929-39. PubMed ID: 25625541
[TBL] [Abstract][Full Text] [Related]
17. ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.
Bandarage UK; Cao J; Come JH; Court JJ; Gao H; Jacobs MD; Marhefka C; Nanthakumar S; Green J
Bioorg Med Chem Lett; 2018 Aug; 28(15):2622-2626. PubMed ID: 30082069
[TBL] [Abstract][Full Text] [Related]
18. Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.
Laufer R; Ng G; Liu Y; Patel NK; Edwards LG; Lang Y; Li SW; Feher M; Awrey DE; Leung G; Beletskaya I; Plotnikova O; Mason JM; Hodgson R; Wei X; Mao G; Luo X; Huang P; Green E; Kiarash R; Lin DC; Harris-Brandts M; Ban F; Nadeem V; Mak TW; Pan GJ; Qiu W; Chirgadze NY; Pauls HW
Bioorg Med Chem; 2014 Sep; 22(17):4968-97. PubMed ID: 25043312
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.
Jiang JK; Huang X; Shamim K; Patel PR; Lee A; Wang AQ; Nguyen K; Tawa G; Cuny GD; Yu PB; Zheng W; Xu X; Sanderson P; Huang W
Bioorg Med Chem Lett; 2018 Nov; 28(20):3356-3362. PubMed ID: 30227946
[TBL] [Abstract][Full Text] [Related]
20. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
